Results 61 to 70 of about 561,728 (244)

Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome [PDF]

open access: yes, 2010
AIMS: Diabetic cardiomyopathy, characterized by left ventricular (LV) dysfunction and LV hypertrophy independent of myocardial ischaemia and hypertension, could contribute to the increased life-time risk of congestive heart failure seen in patients with ...
Brunner-Larocca, H P   +35 more
core   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

Diabetic Cardiomyopathy [PDF]

open access: yesCirculation Research, 2019
Diabetic cardiomyopathy was initially described as a human pathophysiological condition in which heart failure occurred in the absence of coronary artery disease, hypertension, and valvular heart disease. Recent studies in diabetic animal models identify decreased cardiomyocyte function as an important mediating mechanism for heart failure.
openaire   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba   +10 more
wiley   +1 more source

Sub-clinical diabetic cardiomyopathy - assessment by systolic time intervals

open access: yes, 1981
Left ventricular performance in diabetics wit he at hypertension, ischemic Tie art disease, or clinical evidence of other heart diseases was assessed by systolic time intervals and echo-cardiography. The PEP/ LVET ratio was 3.48% higher in diabetics than
Lakshmikanthan, C.   +6 more
core   +1 more source

Proteomic Analysis in Diabetic Cardiomyopathy using Bioinformatics Approach

open access: yes, 2008
Diabetic cardiomyopathy is a distinct clinical entity that produces asymptomatic heart failure in diabetic patients without evidence of coronary artery disease and hypertension.
M.R. Narasinga Rao   +9 more
core   +3 more sources

Emerging role of epigenetics and miRNA in diabetic cardiomyopathy

open access: yes, 2013
The prevalence of heart failure independent of coronary artery disease and hypertension is increasing rapidly in diabetic patients. Thus, this pathophysiology has been recognized as a distinct clinical entity termed "diabetic cardiomyopathy." Several ...
Asrih, Mohamed   +3 more
core   +1 more source

Differentially-expressed genes in 1, 4, and 8-week diabetic dorsal root ganglia (DDRG), and 16-week diabetic cardiomyopathy (DCM).

open access: yes, 2013
Differentially-expressed genes in 1, 4, and 8-week diabetic dorsal root ganglia (DDRG), and 16-week diabetic cardiomyopathy (DCM).
Fang Xie (103933)   +10 more
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy